Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Gates, Wellcome, and Mastercard give $125 million for coronavirus treatments
by Ryan Cross
March 15, 2020
| A version of this story appeared in
Volume 98, Issue 10
A trio of heavy hitters is pitching in up to $125 million in seed funding to launch the COVID-19 Therapeutics Accelerator. The Bill & Melinda Gates Foundation and Wellcome are committing up to $50 million each, and Mastercard has pledged up to $25 million. The accelerator will work with drug companies and government agencies to look for old and new small-molecule and biologic drugs to treat COVID-19, the disease caused by the novel coronavirus.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X